None listed
Conditions
Brief summary
The purpose of this study is to see whether the use of a particular type of PET scan will improve detection rates of cancer, and improve treatment management. Who is it for? You may be eligible for this study if you are aged over 18 and have been referred for radiotherapy after a prostatectomy. Study details All participants in this study will be required to undergo a PET/CT scan and a diagnostic CT Chest/Abdomen Pelvis You will also be asked to fill out a quality of life Questionnaire. before and after commencing radiotherapy. You will be reviewed as part of your routine care with a routine blood test which will monitor your PSA levels at these visits you will be asked to complete a quality of life Questionnaire. It is hoped this research will determine if the use of PET scanning in treatment planning and how it influences radiation treatment planning in patients will improve treatment outcomes for patients with prostate cancer.
Interventions
18FDCPyL is an investigational radioactive diagnostic imaging agent indicated for positron emissiontomography (PET) in patients with cancer where knowledge of the distribution of Prostate SpecificMembrane Antigen (PSMA) throughout the body.
To assess the role and impact of a new imaging scan, 18FDCPyLPET in patients referred for
salvage radiotherapy (radiation treatment when prostate cancer has recurred) following radical prostatectomy forprostate cancer. 18FDCPyLPET/CT has previously shown to p
18FDCPyL is an investigational radioactive diagnostic imaging agent indicated for positron emissiontomography (PET) in patients with cancer where knowledge of the distribution of Prostate SpecificMembrane Antigen (PSMA) throughout the body. To assess the role and impact of a new imaging scan, 18FDCPyLPET in patients referred for salvage radiotherapy (radiation treatment when prostate cancer has recurred) following radical prostatectomy forprostate cancer. 18FDCPyLPET/CT has previously shown to provide high resolution imagery in targeted areas Participants will have an 18FDCPyLPET/CT scan, in which the results will determine what management pathway best suits them. Participants will be required to have 1 PET/CT scan this scan will take approximately 2 hours. The PET imaging will be performed in the imaging department by qualified Nuclear Medicine Specialists 250 MBq +/50 MBq, depending on patient weight and activity provided on day of scan
Sponsors
GenesisCare Cancer Care Research
Study design
Allocation
Non-randomised trial
Primary purpose
Treatment
Eligibility
Sex/Gender
Male
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Men being referred and suitable for radiotherapy to the prostate-bed and/or pelvis. Biochemical recurrence defined as PSA greater than 0.2 ng/mL and less than2.0 ng/mL Prior radical prostatectomy with or without pelvic lymph node dissection Staging immediately prior to prostatectomy showed no evidence of metastatic disease: TanyNanyM0. Any prior imaging permitted including CT, bone scan and previous functional imaging scans. Pathological staging following prostatectomy: pTany, pNany Histopathology of Acinar adenocarcinoma or ductal carcinoma Age over 18 years PSA within 4 weeks of PET/CT
Exclusion criteria
Established distant metastases No prior pelvic or prostate bed radiotherapy Prostate cancer with significant sarcomatoid or neuroendocrine small cell components Significant intercurrent morbidity that, in the judgement of the investigator, would limit compliance with the study protocols Current androgen deprivation therapy or anti-androgen therapy
Outcome results
None listed